Abstract
Background
We studied the extent of BRCA1/2 genetic testing to help select the surgical approach for patients with breast cancer
in Japan remains unclear.
Patients and Methods
The study subjects were female patients with primary unilateral invasive breast cancer
considered as candidates for breast-conserving surgery who underwent preoperative
BRCA1/2 genetic testing. A retrospective analysis was performed on the results of BRCA1/2 genetic testing and surgical method selection using national registration data from
the Japanese Hereditary Breast and Ovarian Cancer Syndrome Consortium.
Results
Our study included 318 female patients. Among these patients, 23.7% of patients with
BRCA1/2 mutations and 61.8% of patients without these variants underwent breast-conserving
surgery (P < .01). Among the patients with BRCA1/2 mutations, those who chose breast-conserving surgery tended not to undergo risk-reducing
salpingo-oophorectomy (P < .05). Among the patients with BRCA1/2 mutations who underwent mastectomy for the affected side, 31.8% received contralateral
risk-reducing mastectomy. Patients diagnosed with breast cancer under the age of 50
years were more likely to have contralateral risk-reducing mastectomy than patients
over the age 50 years (P < .05).
Conclusions
Patients with BRCA1/2 mutations tend to choose mastectomy. However, it is speculated that the final surgical
method selection is made in consideration of not only the test results but also with
careful consideration of the patient, taking into account other factors including
individual values for risk-reducing surgeries and the age of breast cancer onset.
Keywords
To read this article in full you will need to make a payment
Subscribe to Clinical Breast Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.Jpn J Clin Oncol. 2015; 45: 884-891
- Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients.J Clin Oncol. 2019; 37: 1305-1315
- Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients.Clin Cancer Res. 2017; 23: 6113-6119
- Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.Nat Commun. 2018; 9: 4083
- Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol. 2007; 25: 1329-1333
- Prognosis of BRCA-associated breast cancer: a summary of evidence.Breast Cancer Res Treat. 2010; 119: 13-24
- Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.Breast Cancer Res Treat. 2014; 144: 443-455
- Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis.Breast. 2014; 23: 721-742
- Rapid genetic counseling and testing in newly diagnosed breast cancer: patients’ and health professionals’ attitudes, experiences, and evaluation of effects on treatment decision making.J Surg Oncol. 2017; 116: 1029-1039
- NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Ver.3. 2019.(Available at:)https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/Date accessed: October 7, 2019
- Clinical Guidelines of Breast Cancer (2) Epidemiology/Diagnosis, 2018 edition.Kanahara Publishing Co, Tokyo2018: 320
- Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.Cancer Sci. 2008; 99: 1967-1976
- Prevalence and differentiation of hereditary breast and ovarian cancers in Japan.Breast Cancer. 2015; 22: 462-468
- Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.Breast Cancer. 2014; 21: 656-663
- Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.J Hum Genet. 2018; 63: 447-457
- Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.J Natl Cancer Inst. 2009; 101: 80-87
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA. 2010; 304: 967-975
- Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.J Clin Oncol. 2004; 22: 1823-1829
- A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.Ann Oncol. 2014; 25: 57-63
- Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.Br J Cancer. 2014; 110: 1081-1087
- Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer.Ann Surg Oncol. 2016; 23: 3232-3238
- Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Br J Cancer. 2011; 104: 1384-1392
- Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.Br J Cancer. 2000; 83: 384-386
- The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.Breast Cancer Res. 2012; 14: R156
- Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.J Clin Oncol. 2010; 28: 2404-2410
Article Info
Publication History
Published online: August 19, 2020
Accepted:
August 10,
2020
Received in revised form:
July 27,
2020
Received:
February 7,
2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
